[CLSTR]
< Back to situations

[ORGANIZATION]

Duchenne muscular dystrophy

Featured in 10 tracked stories · first seen

Situations

[QUIET] [BUSINESS] [US]

Deramiocel trial, FDA pivot, and ongoing lawsuit

5 clusters · 21 sources · last updated

Latest: Capricor Therapeutics pivots regulatory strategy amid legal challenges

Capricor Therapeutics is navigating a shifting regulatory and strategic landscape following an FDA advisory committee vote against the original effectiveness case for deramiocel in treating Duchenne cardiomyopathy. In re

[QUIET] [HEALTH] [BR] [US]

Duchenne muscular dystrophy drug regulation in Brazil

2 clusters · 35 sources · last updated

Latest: Anvisa and Roche cancel Elevidys registration in Brazil

In August 2026, Brazil’s National Health Surveillance Agency (Anvisa) issued two significant regulatory decisions regarding treatments for Duchenne muscular dystrophy (DMD). First, Anvisa approved the registration of Du

Also covered in